Alkem Laboratories

Alkem focuses on gastroenterology therapies, including gastroesophageal reflux disease (GERD).

Alkem Labs has successfully made it to the top 10 companies in the CNS therapy and neuro therapy

Alkem is a leader in India’s ophthalmology pharmaceutical sector.

Alkem is one of the biggest names in the generic and speciality pharmaceutical sector in India

Alkem’s India sales grew 9.7% year-over-year in Q3FY23, reaching ₹19,922 million.

Alkem is a major player in India’s generic and specialty pharmaceutical sector.

Samprada Singh founded Alkem Labs in 1973, transforming the Indian pharmaceutical industry.

The inspirational journey of Alkem began in 1973, and ever since its inception, it has changed the world of pharmaceuticals through its contributions.

Alkem has a system for addressing investor grievances.

Alkem Labs provides contact information for clients, customers, and job seekers.

Alkem is the 3rd largest Indian pharmaceutical company in terms of total prescriptions generated and the 6th largest in terms of revenues (IMS).

Alkem Laboratories has a pharmacovigilance system to safeguard patient health through communication of medicine-related adverse events.

Alkem Labs operates 19 manufacturing units, holds 800 brands, and serves 40 countries.

Alkem Laboratories Ltd releases its Q2 2027 earnings results. Analyst firm GF Value projects a 32% upside potential based on the upcoming report. The company operates in the pharmaceutical sector, specializing in generic drugs and active pharmaceutical ingredients (APIs). Investors monitor the earnings for guidance on financial performance and market positioning.

Nov 2026Yahoo FinanceNews article

The **USFDA issued a Form 483** to **Alkem Labs’ subsidiary Enzene Biosciences at its Chakan plant**, citing **six observations** during an inspection. The inspection was completed on **February 13, 2026**, marking a regulatory review for the facility.

Feb 2026RediffNews article

Alkem MedTech secures an agreement with Exactech to produce and distribute Exactech’s knee and hip replacement implants in India. The deal marks Alkem’s expansion into medical device manufacturing, leveraging Exactech’s global implant technology. Both companies aim to strengthen India’s orthopedic device market through this collaboration.

Aug 2024PR NewswireNews article

Alkem Laboratories Ltd received **10 observations** from the **US Food and Drug Administration (USFDA)** after an inspection at its **Baddi manufacturing facility**. The inspection took place between **March 19–27, 2024**, covering compliance and operational standards. The company acknowledged the findings but did not disclose specific details.

Mar 2024CNBCTV18News article